Disclosed are improved pharmaceutical formulations comprising dehydroepiandrosterone
(DHEA), enriched in selected polymorphic forms, for therapeutic applications. In
one embodiment, the formulation comprises, in solid form, DHEA, at least 85% of
which is present as a single polymorph selected from the form I polymorph or the
form II polymorph, and at least one pharmaceutical excipient. Methods for making
and using such compositions are also disclosed.